Combination Therapy for Advanced Pancreatic Cancer
Author Information
Author(s): Scheithauer W, Kornek G V, Raderer M, Hejna M, Valencak J, Miholic J, Kovats E, Lang F, Funovics J, Bareck E, Depisch D
Primary Institution: Vienna University Medical School
Hypothesis
Can combining gemcitabine with epirubicin and G-CSF improve treatment outcomes in patients with advanced pancreatic adenocarcinoma?
Conclusion
The combination of gemcitabine, epirubicin, and G-CSF appears to be an effective palliative treatment for patients with metastatic pancreatic adenocarcinoma, with moderate side effects.
Supporting Evidence
- One patient achieved complete remission and 13 achieved partial remission, resulting in a 21% overall response rate.
- The median survival time for patients was 7.8 months.
- 43% of patients with tumor-related symptoms experienced significant palliation.
Takeaway
This study tested a new mix of medicines to help people with a serious type of cancer, and it worked pretty well without causing too many problems.
Methodology
Patients received a combination of epirubicin, gemcitabine, and G-CSF in a multicenter trial, with efficacy assessed through objective response and clinical benefit response.
Limitations
The study results need confirmation in a randomized trial.
Participant Demographics
Patients with metastatic pancreatic adenocarcinoma.
Statistical Information
Confidence Interval
95% CI, 12–33%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website